Evan Seigerman
Evan Seigerman is a biopharma specialist at BMO, known for his insights into the pharmaceutical sector. Recently, he revised the revenue forecast for Merck's Gardasil vaccine due to declining demand, highlighting the challenges that the company faces in regaining investor trust amid market fluctuations.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 2 | 5.00 | 0.04% | +10% | 331,002,651 | 161,608 | $21,000,000 | 10,253$ |
| Canada | 1 | 7.00 | 0.04% | +0% | 38,005,238 | 16,662 | $1,700,000 | 745$ |
| Totals | 3 | 369,007,889 | 178,270 | $22,700,000 | 10,998$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Evan Seigerman, a BMO Capital Markets analyst, commented on the tolerable profile of orforglipron.
7
United States:
Evan Seigerman, a pharmaceuticals analyst with BMO Capital Markets, wrote that the industry is not expected to make any major changes.
5
United States:
Evan Seigerman, a pharmaceuticals analyst with financial firm BMO Capital Markets, expressed skepticism about the effectiveness of tariffs in bringing drug manufacturing back to the US.
5
Switzerland:
Evan Seigerman, a biopharma specialist at BMO, reduced the revenue forecast for Gardasil this year by 13%.
5